Table 4.

−219 G→T allele and genotype distributions in patients with AD and control subjects by center and odds ratios for developing AD according to the −219 TT genotype adjusted for sex, age, and center

Location of centerAllele frequencyGenotype distribution (%)OR (95% CI) TT vs GT+GG
nGTGGGTTT
OR = odds ratio.
Finland
    AD cases1090.510.4931 (0.28)49 (0.45)29 (0.27)3.3 (1.7–6.3)
    Controls1880.630.3767 (0.36)102 (0.54)19 (0.10)p < 0.0003
UK
    AD cases2750.420.5857 (0.21)118 (0.43)100 (0.36)1.9 (1.3–2.9)
    Controls2030.520.4858 (0.29)97 (0.47)48 (0.24)p < 0.003
France
    AD cases6750.440.56120 (0.18)361 (0.53)194 (0.29)1.5 (1.1–1.9)
    Controls6570.550.45206 (0.31)309 (0.47)142 (0.22)p < 0.003
Spain
    AD cases1160.470.5327 (0.23)55 (0.47)34 (0.29)1.5 (0.8–2.7)
    Controls1330.530.4737 (0.28)67 (0.50)29 (0.21)p < 0.17
Minnesota, USA
    AD cases2960.470.5363 (0.21)152 (0.51)81 (0.27)1.5 (1.1–2.1)
    Controls4630.540.46130 (0.28)240 (0.52)93 (0.20)p < 0.02
St. Louis, Missouri, USA
    AD cases2610.490.5162 (0.24)130 (0.50)69 (0.26)1.3 (0.9–2.0)
    Controls2820.510.4968 (0.24)152 (0.54)62 (0.22)p < 0.18
Total
    AD cases1,7320.460.54360 (0.21)865 (0.50)507 (0.29)1.6 (1.3–1.8)
    Controls1,9260.540.46567 (0.29)966 (0.50)393 (0.21)p < 0.0001